Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalolitovolrelimab plus TP neoadjuvant therapy in locally advanced cervical cancer
ChiCTR2500108418Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apalolitovolrelimab in Cervical Cancer (CC), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Objective Response Rate. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
apalolitovolrelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500108418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108418.